Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen And Partners Tackle ALS R&D
by Rick Mullin
July 23, 2012
| A version of this story appeared in
Volume 90, Issue 30
Biogen Idec, the Center for Human Genome Variation at Duke University, and the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., will work together to sequence the genomes of patients with amyotrophic lateral sclerosis (ALS). Aided by researchers at other institutions, the partners plan to sequence the genomes of approximately 500 patients over the next two years and 1,000 patients within five years. Biogen is providing an undisclosed amount of funding to the collaboration.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X